Topic Archives: Cortexyme (CRTX)

I got several reader questions this week about a new recommendation from Dave Lashmet at Stansberry — it looks like this was issued as a recommendation for regular Stansberry Investment Advisory subscribers, not one of Lashmet’s more expensive biotech-focused newsletters, and it’s very light on clues… but let’s see if we can give you anything […]

Comments

No comments.

We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

More Info